EGFR and non-small cell lung carcinoma: Mechanistic studies have shown that IPTF effectively represses the malignant proliferation phenotype of non-small cell lung cancer A549 cells by synergistically inhibiting two key signaling pathways: PI3K/AKT and EGFR-MAPK.